OncoSec Medical immunotherapy helps reduce tumors in mice

OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.

While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.

OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)

Comments (4)
  • TruffelPig
    , contributor
    Comments (4206) | Send Message
    It is obvious important to mention that clinical trials are ongoing in $ONCS. There are currently 3 phase II clinical trials and they got good data recently in humans:http://bit.ly/19cr029
    8 Oct 2013, 07:59 AM Reply Like
  • rhancock
    , contributor
    Comments (5) | Send Message
    $ONCS.OB....good science and has shown great results already. Great time to get in this stock
    8 Oct 2013, 10:22 AM Reply Like
  • Robbster
    , contributor
    Comments (47) | Send Message
    Yep, I'm with you on $ONCS.OB.
    8 Oct 2013, 11:15 PM Reply Like
  • Tile
    , contributor
    Comments (112) | Send Message
    8 Dec 2013, 10:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs